Press Releases

 
Press Releases
  Date Title and Summary View
Sep 4, 2015
REDWOOD CITY, Calif., Sept. 4, 2015 (GLOBE NEWSWIRE) -- Relypsa, Inc. (Nasdaq:RLYP), a biopharmaceutical company, today announced that on September 1, 2015, the compensation committee of the company's board of directors granted 14 new employees options to purchase an aggregate of 80,800 shares of the company's common stock with a per share exercise...
Sep 2, 2015
REDWOOD CITY, Calif., Sept. 2, 2015 (GLOBE NEWSWIRE) -- Relypsa, Inc. (Nasdaq:RLYP) today announced that the company will present at two upcoming investor conferences in September 2015. Kristine M. Ball, senior vice president and chief financial officer, will present at the 22nd Annual NewsMakers in the Biotech Industry Conference, Se...
Aug 18, 2015
REDWOOD CITY, Calif., Aug. 18, 2015 (GLOBE NEWSWIRE) -- Relypsa, Inc. (Nasdaq:RLYP), a biopharmaceutical company, today announced that on August 17, 2015, the compensation committee of the company's board of directors granted eight new employees options to purchase an aggregate of 51,500 shares of the company's common stock with a per share exercis...
Aug 10, 2015
REDWOOD CITY, Calif., Aug. 10, 2015 (GLOBE NEWSWIRE) -- Relypsa Inc. (NASDAQ:RLYP), a biopharmaceutical company, today announced it has entered a two-year detailing agreement with Sanofi for Patiromer for Oral Suspension (Patiromer FOS). Patiromer FOS is Relypsa's investigational medicine that is currently under review for the treatment of hyperkal...
Aug 10, 2015
REDWOOD CITY, Calif., and ST. GALLEN, Switzerland, Aug. 10, 2015 (GLOBE NEWSWIRE) -- Relypsa, Inc. (NASDAQ:RLYP), a biopharmaceutical company, and Vifor Fresenius Medical Care Renal Pharma Ltd. (VFMCRP), a common company of Galenica and Fresenius Medical Care, today announced they have entered into an exclusive partnership to commercialize Patirome...
Aug 6, 2015
REDWOOD CITY, Calif., Aug. 6, 2015 (GLOBE NEWSWIRE) -- Relypsa, Inc. (NASDAQ:RLYP), a biopharmaceutical company, today reported financial results for the quarter ended June 30, 2015. Net loss for the second quarter 2015 was $39.3 million, or $0.95 per share, compared to $16.7 million, or $0.51 per share, for the comparable period in 2014. C...
Aug 5, 2015
REDWOOD CITY, Calif., Aug. 5, 2015 (GLOBE NEWSWIRE) -- Relypsa, Inc. (Nasdaq:RLYP), a biopharmaceutical company, today announced that on August 3, 2015, the compensation committee of the company's board of directors granted six new employees options to purchase an aggregate of 20,300 shares of the company's common stock with a per share exercise pr...
Aug 3, 2015
REDWOOD CITY, Calif., Aug. 3, 2015 (GLOBE NEWSWIRE) -- Relypsa, Inc. (Nasdaq:RLYP), today announced that John A. Orwin, president and chief executive officer, will present at the 2015 Wedbush PacGrow Healthcare Conference on August 11, 2015 at 9:45 a.m. ET. To access the live webcast and subsequent archived recording of this presentation, p...
Jul 24, 2015
REDWOOD CITY, Calif., July 24, 2015 (GLOBE NEWSWIRE) -- Relypsa, Inc. (Nasdaq:RLYP), a biopharmaceutical company, today announced that on July 15, 2015, the compensation committee of the company's board of directors granted six new employees options to purchase an aggregate of 32,900 shares of the company's common stock with a per share exercise pr...
Jul 14, 2015
Patiromer FOS significantly decreased blood potassium levels in patients with chronic kidney disease and hyperkalemia at four weeks (primary endpoint) Potassium levels were maintained at normal levels through 52 weeks of treatment Patiromer FOS was well tolerated when used chronically and the safety profile was consistent with t...
Page:
1
... NextLast
= add release to Briefcase